Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average - Time to Sell?

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.22 and traded as low as $2.09. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 52,897 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th.

Oramed Pharmaceuticals Stock Performance

The stock's 50-day moving average price is $2.15 and its 200-day moving average price is $2.21. The company has a market capitalization of $86.56 million, a price-to-earnings ratio of -5.99 and a beta of 1.60.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). Analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BML Capital Management LLC raised its stake in Oramed Pharmaceuticals by 2.1% in the 2nd quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company's stock valued at $6,937,000 after purchasing an additional 62,505 shares during the last quarter. Boothbay Fund Management LLC raised its stake in Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares during the last quarter. Peapod Lane Capital LLC raised its stake in Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.